Related Experiment Video

Updated: Jun 21, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Jeffrey A Engelman1

  • 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02129, USA. jengelman@partners.org

Nature Reviews. Cancer
|July 25, 2009
PubMed

Insights

Targeting the PI3K-Akt pathway shows therapeutic potential for cancer treatment. This review discusses strategies, suitable cancers, and clinical development challenges for PI3K-Akt inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide 3-kinase/Akt (PI3K-Akt) pathway is crucial for cancer cell growth and survival.
  • Genetic and laboratory evidence strongly supports the pathway's role in tumorigenesis.
  • Targeted therapies inhibiting this pathway are rapidly advancing into clinical use.

Purpose of the Study:

  • To review the therapeutic potential of targeting the PI3K-Akt signaling pathway in cancer treatment.
  • To analyze the advantages and disadvantages of various targeting strategies.
  • To identify cancers most likely to respond and discuss clinical development challenges.

Main Methods:

  • Literature review of genetic and laboratory studies.
  • Analysis of clinical trial data and research on PI3K-Akt inhibitors.
  • Discussion of therapeutic strategies, cancer-specific responses, and clinical limitations.

Main Results:

  • The PI3K-Akt pathway is a validated target for anti-cancer drug development.
  • Different inhibitors and targeting strategies offer varied efficacy and toxicity profiles.
  • Clinical development faces challenges including resistance, toxicity, and patient selection.

Conclusions:

  • Targeting the PI3K-Akt pathway holds significant promise for cancer therapy.
  • Optimizing treatment strategies and overcoming clinical hurdles are essential for successful drug development.
  • Further research is needed to refine patient selection and combination therapies.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...